Using the immunocompetent and syngeneic MBT-2 murine model, we first observed that treatment with anti–PD-1 mAb decreased tumor growth and resulted in a complete response in typically one out of six male mice, about half the number observed in female mice (Fig. 3A–C). This evidence concerns the gene PDCD1 and neoplasm.